- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
The Medicare demonstration that caps beneficiaries’ monthly insulin costs might be a model to consider for other highly rebated drugs that treat chronic conditions, if Congress fails to overhaul Part D, a congressional Medicare adviser said Friday (Jan. 14).
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us